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OBJECTIVE — Carbohydrate counting is an effective approach to mealtime insulin adjust-
ment in type 1 diabetes but has not been rigorously assessed in type 2 diabetes. We sought to
compare an insulin-to-carbohydrate ratio with a simple algorithm for adjusting the dose of
prandial insulin glusiline.
RESEARCH AND DESIGN METHODS — This 24-week, multicenter, randomized,
controlled study compared two algorithms for adjusting mealtime (glulisine) insulin along with
a standard algorithm for adjusting background (glargine) insulin in 273 intent-to-treat patients
with type 2 diabetes. Glulisine and glargine were adjusted weekly in both groups based on
self-monitored blood glucose (SMBG) results from the previous week. The simple algorithm
group was provided set doses of glulisine to take before each meal. The carbohydrate counting
(carb count) group was provided an insulin-to-carbohydrate ratio to use for each meal and
adjusted their glulisine dose based on the amount of carbohydrate consumed.
RESULTS — A1C levels at week 24 were 6.70% (simple algorithm) and 6.54% (carb count).
The respective mean A1C changes from baseline to 24 weeks were 1.46 and 1.59% (P 
0.24). A1C 7.0% was achieved by 73.2% (simple algorithm) and 69.2% (carb count) (P 
0.70) of subjects; respective values for A1C 6.5% were 44.3 and 49.5% (P  0.28). The total
dailydoseofinsulinwaslower,andtherewasatrendtowardlessweightgainincarbcountgroup
patients. Severe hypoglycemia rates were low and equal in the two groups.
CONCLUSIONS — Weekly basal-bolus insulin adjustments based on premeal and bedtime
glucose patterns resulted in signiﬁcant reductions in A1C. Having two effective approaches to
delivering and adjusting rapid-acting mealtime insulin may increase physicians’ and patients’
willingness to advance therapy to a basal-bolus insulin regimen.
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levated A1C and postprandial glu-
cose levels have been related to risk
for long-term complications in dia-
betes (1–3). Insulin therapy is often
needed to achieve target A1C and post-
prandial glucose levels in type 2 diabetes
(4). Although many insulin regimens are
available, in this study we examined the
use of a physiological regimen that in-
cludes a long-acting insulin to provide a
basal insulin level for the entire day and a
rapid-acting insulin for bolus administra-
tion at mealtimes (5,6).
Establishing the optimal mealtime in-
sulin dose in basal-bolus therapy may be
difﬁcult because it often involves calcula-
tions that consider multiple factors such
as current blood glucose, target blood
glucose, insulin-to-carbohydrate ratios,
total carbohydrate content of meals, and
activity levels (7). Insulin delivery based
on carbohydrate counting is the gold
standard for improving glycemic control
in type 1 diabetes (8,9) but is difﬁcult for
some patients (10,11). Neither large, ran-
domized studies of intensive basal-bolus
analoginsulintherapyinpatientswithtype
2 diabetes nor studies evaluating the
efﬁcacy of carbohydrate counting in type 2
diabetes have been conducted. In this 24-
week study we compared an insulin-to-
carbohydrate ratio with a simple pattern
control–based algorithm for adjusting the
dose of prandial insulin glulisine.
RESEARCH DESIGN AND
METHODS— This multicenter, con-
trolled,open,randomized,parallel-group
study included 2 weeks of screening fol-
lowed by 24 weeks of treatment. Ran-
domization (1:1) was balanced by
metformin administration, baseline num-
ber of insulin injections, injection with
pen versus syringe and vial, and study
center. The study complied with the In-
ternationalCouncilonHarmonizationE6
guideline of May 1996 and with the ethi-
cal principles of the Declaration of Hel-
sinki. Institutional review boards
approved the protocol and study docu-
ments. All patients provided informed
written consent.
Participantswereaged18–70years,
had type 2 diabetes for 6 months, had
A1C of 7–10% at screening, and had
taken 2 insulin injections/day (36%
taking 2 injections and 64% taking 2
injections) with or without metformin
(one-third were taking metformin) for
3 months before study entry. Upon
entry into the study, 37% were using
glargine and at least one injection of a
rapid-acting insulin analog, 36% were
using a premixed insulin, and the re-
mainder were using a mix of various
other regimens. Reasons for exclusion
were treatment with oral antidiabetic
drugs (except metformin) within 3
months before study entry; pregnancy
planning, pregnancy, or lactation; se-
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(1.4 mg/dl in women) taking met-
formin and 3.0 mg/dl for any subject;
clinicallysigniﬁcantrenaldisease(other
than proteinuria); hepatic disease; New
York Heart Association class III–IV
heart failure; or any disease or condi-
tion that might interfere with study
completion.
Treatments
Targets were fasting blood glucose 95
mg/dl,preprandial(beforelunchanddin-
ner)bloodglucose100mg/dl,andbed-
time blood glucose 130 mg/dl.
Insulin glargine dosing. The initial in-
sulin glargine dose was calculated as 50%
of the prerandomization total daily insu-
lin dose. Subsequently, dosing was ti-
trated weekly according to the mean of
the last 3 days of fasting self-monitored
blood glucose (SMBG) (Table 1). A dose
increase could be split into 2 incre-
ments over the week.
Insulin glulisine dosing. The remain-
ing 50% of the total daily insulin dose
was used for mealtime insulin glulisine,
which was split to cover three meals:
50% for the largest (most carbohydrate)
meal, 33% for the middle-sized meal,
and17%forthesmallestmeal.Glulisine
dose adjustment for both groups was
based on prelunch/dinner and bedtime
(these three time points are referred to
as mealtime) blood glucose patterns
from the previous week as shown in Ta-
ble 1. Simple algorithm patients’ pre-
meal doses were set weekly, based on
the algorithm in Table 1. Study staff
taught the carbohydrate counting (carb
count) group about carbohydrate
counting and how to use an insulin-to-
carbohydrate ratio. The insulin-to-
carbohydrate ratios for each meal were
determined based on the algorithm in
Table 1. An insulin-to-carbohydrate ra-
tioallowspatientstoadjusttheirinsulin
based on the amount of carbohydrate
they choose to eat at a meal.
Additional antidiabetic medications.
Patients taking metformin at randomiza-
tion continued using it at the same dose.
No other insulin or oral antidiabetic
agents were permitted.
Dietary and lifestyle
recommendations
Educational materials were specially de-
signed for this study based on the Inter-
national Diabetes Center Type 2 Diabetes
BASICSclientbook(12).Thematerialsfor
the simple algorithm group omitted all
references to carbohydrate intake except
in the context of treating hypoglycemia
and having carbohydrate if alcohol was
being consumed.
Patient diaries and study visits
Diaries. All patients recorded SMBG be-
fore meals and at bedtime, insulin doses,
food and estimated carbohydrate intake
per meal (carb count group), information
related to hypoglycemia, activity level,
and a 7-point blood glucose proﬁle at
weeks 0, 12, 18, and 24.
Visits. Study visits occurred at screen-
ing, at baseline, and at weeks 2, 6, 12, 18,
and 24 (end point). Evaluations included
physical examinations, vital signs, elec-
Table 1—Insulin glargine and insulin glulisine dose adjustment based on pattern of mealtime blood glucose values for the past week
Insulin glargine adjustments: both groups
Mean of last 3-day fasting SMBG mg/dl Adjustment
180 mg/dl Increase 8 units
140–180 mg/dl Increase 6 units
120–139 mg/dl Increase 4 units
95–119 mg/dl Increase 2units
70–94 mg/dl No change
70 mg/dl Decrease by the same number of units as insulin glulisine increase that titration week or up to 10% of
total insulin glargine dose
Insulin glulisine adjustments: simple algorithm group
Mealtime dose Pattern of mealtime blood glucose values below
target*
Pattern of mealtime blood glucose values above
target†
10 units Decrease by 1 unit Increase by 1 unit
11–19 units Decrease by 2 units Increase by 2 units
20 units Decrease by 3 units Increase by 3 units
Insulin glulisine adjustments: carbohydrate counting (insulin-to-carbohydrate ratio) group‡
Mealtime dose Pattern of mealtime blood glucose values below
target*
Pattern of mealtime blood glucose values above
target
†
1 unit/20 g Decrease to 1 unit/25 g Increase to 1 unit/15 g
1 unit/15 g Decrease to 1 unit/20 g Increase to 1 unit/10 g
1 unit/10 g Decrease to 1 unit/15 g Increase to 2 units/15 g
2 units/15 g Decrease to 1 unit/10 g Increase to 3 units/15 g
3 units/15 g§ Decrease to 2 units/15 g Increase to 4 units/15 g
*Ifmorethanone-halfofthemealtimebloodglucosevaluesfortheweekwerebelowtarget.†Ifmorethanone-halfofthemealtimebloodglucosevaluesfortheweek
wereabovetarget.‡Eachpatientinthecarbcountgroupwasalsogivenascheduleforamealtimeinsulinglulisinecorrectiondosetoaddafewunitsifhighorsubtract
a few units if low. §Increase mealtime insulin as needed following this pattern.
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chemistry laboratory tests, and diary re-
view. Adverse events, hypoglycemic epi-
sodes,andconcomitantmedicationswere
recorded. There was weekly contact ei-
ther by a study visit or a phone call to
review diaries and adjust insulin doses.
Efﬁcacy and safety variables
Efﬁcacy. The primary end point was the
change in A1C from baseline to week 24.
Secondary variables were change in A1C
from baseline to individual study time
points; changes from baseline to week 24
in fasting plasma glucose (FPG); prepran-
dial and postprandial blood glucose;
7-point blood glucose proﬁle; average
basal, bolus, and total insulin doses; lip-
ids; percentages of patients achieving
A1C 7.0 and 6.5% at week 24; and
weight gain.
Safety. Alladverseeventswererecorded.
Clinicalchemistryandhematologyvalues
and physical examination results, includ-
ing weight and vital signs, were
documented.
Hypoglycemia
Severe hypoglycemia was deﬁned as re-
quiring assistance and involved either
SMBG 36 mg/dl or treatment with oral
carbohydrates, intravenous glucose, or
glucagon, with a prompt response to that
therapy. Symptomatic hypoglycemia was
also documented.
Data analysis
Populations. The safety population in-
cluded patients who took 1 dose of
study medication and had any follow-up
information. The intent-to-treat (ITT)
population included patients evaluated
for safety who had baseline and an on-
therapy observation for 1 efﬁcacy
variable but excluded patients who
never received treatment or who were
treated but had no postbaseline efﬁcacy
assessments.
Sample size. The noninferiority hypoth-
esis was to be tested; a study with 86
evaluable subjects per treatment arm
would have 90% power to detect treat-
ment differences of 0.5%. The SD of 
1.0 used in the power computations cor-
responds to the 95% upper conﬁdence
limit of the SD of the A1C change from a
previous insulin glulisine trial.
Statistical methodology. A mixed-
model repeated-measures analysis in-
cluding covariates baseline A1C, number
of daily injections before the study (2 or
2),metforminuseatrandomization,in-
jection method (pen or vial), and study
site provided adjusted estimates and
changes from baseline by visit for weeks
2,6,12,18,and24forA1C,FPG,7-point
blood glucose proﬁle, basal and bolus in-
sulin doses, lipids, weight, and BMI. Per-
centages of patients achieving A1C 7.0
and 6.5% were analyzed by logistic re-
gression that included treatment arm,
baseline A1C, and other randomization
factors. A Poisson regression model, in-
corporating overdispersion, was used to
analyze the rate of hypoglycemia, and a
logistic regression model was used to an-
alyze incidence of hypoglycemia.
RESULTS— Of 281 patients random-
ized, 273 comprised the ITT population
(Table 2) (136 simple algorithm and 137
carb count) (Fig. 1). Forty ITT patients
(12 simple algorithm and 28 carb count)
discontinued treatment.
Primary efﬁcacy analysis
For the primary efﬁcacy analysis,
ANCOVA was used to compare change
from baseline in A1C at week 24 after ad-
justmentforbaselineA1C.Noninferiority
of the simple algorithm compared with
carb count was established because the
mean A1C improved in both treatment
armstoasimilardegree(simplealgorithm
1.46% decrease; carb count 1.59% de-
crease), and the 95% conﬁdence bounds
on the mean difference were well within
the noninferiority margin of 0.5% speci-
ﬁed in the study protocol (week 24: carb
count  simple algorithm  0.13%)
with 95% conﬁdence bounds (0.35 to
0.09%).
Secondary efﬁcacy analyses
A1C levels at week 24 were 6.70% (sim-
ple algorithm) and 6.54% (carb count)
(Fig. 2A); at each time point, changes
from baseline were statistically signiﬁcant
withbothtreatments(P0.0001).By12
weeks both groups had achieved an aver-
age A1C of 7.0%. At the end point,
73.0% (simple algorithm) and 69.2%
(carb count) of patients had A1C 7.0%
(P  0.70); respective values for A1C
6.5% were 44.3 and 49.5% (P  0.28).
By week 24, both arms had signiﬁ-
cantly improved FPG adjusted means
from baseline (simple algorithm 112.0
mg/dl; carb count 101.8 mg/dl; P 
0.0001 for both). The change from base-
line was 40.4 mg/dl in the simple algo-
rithm group patients and 50.6 mg/dl in
thecarbcountgrouppatients(P0.059)
(Fig. 2B). By 12 weeks the average FPG
was 108 mg/dl (simple algorithm) and
112 mg/dl (carb count). Blood glucose
values at each visit declined in both arms,
and the within-group change from base-
line was statistically signiﬁcant over all
daily time points and study visits (Fig.
2C).
Changes in insulin doses
Atbaseline,themeaninsulinglulisine,in-
sulin glargine, and total insulin doses
were 53.9, 53.9, and 107.8 units (simple
algorithm) and 50.5, 50.5, and 100.9
units (carb count), respectively. At week
24, the adjusted mean insulin glulisine
(P  0.0011), insulin glargine (P 
0.0001), and total insulin doses (P 
0.0002) were signiﬁcantly higher in sim-
ple algorithm than in carb count group
patients (108.7, 102.5, and 207.4 units
Safety Population (n=277)
ITT Simple Algorithm, 
no. (%) (n=136)
Discontinuations 12  (8.8)
AEs 3  (2.2)
Protocol violation  3 (2.2)
Lost to follow-up  1 (0.7)
Death       0 (0)
Patient chose not to continue  5 (3.7)
Other 0  (0)
Completed 124  (91.2)
ITT Carb Count, 
no. (%) (n=137)
Discontinuations 28  (20.4)
AEs 6  (4.4)
Protocol violation  6 (4.4)
Lost to follow-up  5 (3.6)
Death 1  (0.7)
Patient chose not to continue  9 (6.6)
Other 3  (2.2)
Completed 109  (79.6)
Figure 1—Disposition of patients. AEs, adverse events.
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tively).At24weeks,thetotalinsulindose
was 1.9 units/kg (simple algorithm
group) and 1.7 units/kg (carb count
group) (see Table 3 of the online appen-
dix available at http://dx.doi.org/
10.2337/dc07-2137).
Lipids
Adjusted mean total cholesterol de-
creasedslightlyinbothgroupsfrombase-
linetoweek24.Asigniﬁcantdecreasewas
observed only for week 12 among the
carb count group patients: from 175.0 to
168.5 mg/dl (8.35 mg/dl; P  0.01).
Neither HDL nor LDL cholesterol
changed signiﬁcantly from baseline to
week 24 in either group; no between-
group differences were observed at week
12 or 24. Triglycerides decreased signiﬁ-
cantly from baseline to week 12 in both
thecarbcount(144.0to128.5mg/dl)and
simple algorithm (164.7 to 148.3 mg/dl)
groups (18.27 mg/dl, P  0.0001 and
15.14 mg/dl, P  0.004, respectively).
There was also a signiﬁcant reduction in
triglycerides from baseline to week 24 in
the carb count (144.0 to 133.0 mg/dl)
group but not in the simple algorithm
(164.7 to 153.4 mg/dl) group (13.19
mg/dl, P  0.008 and 8.19 mg/dl P 
0.170, respectively).
Weight and BMI
Both groups gained weight at 24 weeks:
simple algorithm 3.6 kg (3.4%) and carb
count 2.4 kg (2.3%) (P  0.06 for the
between-group difference at week 24).
Both groups showed a small but signiﬁ-
cant increase in BMI at 24 weeks: simple
algorithm 1.28 kg/m
2 and carb count
0.83kg/m
2(bothP0.0001vs.baseline;
P  0.037 between groups).
Safety
Adverse events. The population used to
determine adverse events and hypoglyce-
mia came from the safety population.
Overall, 102 (73.9%) simple algorithm
and98(70.5%)carbcountgrouppatients
reported 1 treatment-emergent adverse
events.Inbothgroups,themostcommon
adverse events were upper respiratory
tract infection (simple algorithm 17.4%;
carb count 10.8%), nasopharyngitis
(8.7% vs. 5.8%, respectively), sinusitis
(8.0% vs. 6.5%), and inﬂuenza (5.1% vs.
6.5%). Of 42 serious adverse events, 41
were nonfatal: 22 (15.9%) in the simple
algorithm group and 19 (13.7%) in the
carb count group. One death due to
myocardial infarction occurred in the
carb count group. Adverse events
caused six (4.3%) patients in the carb
count group and three (2.2%) patients
in the simple algorithm group to dis-
continue treatment.
Hypoglycemia. The simple algorithm
group had 53 episodes of severe hypogly-
cemia in 19 patients, and the carb count
group had 37 episodes in 19 patients,
leading to estimates of 0.89 and 0.67
events/patient-year for the two groups
(P0.58).SMBG70mg/dlwithsymp-
toms was not statistically signiﬁcant be-
tween the two groups (P  0.08).
However, SMBG 50 mg/dl with symp-
toms was slightly but statistically signiﬁ-
cantly more common in the carb count
group than in the simple algorithm group
(8.0 vs. 4.9 events/patient-year, P 
0.02).
Clinical and laboratory examinations.
Changes from baseline were minor and
not clinically signiﬁcant.
CONCLUSIONS — This is one of the
few randomized controlled trials to eval-
uatebasal-bolusanaloginsulintherapyin
obese patients with type 2 diabetes and
one of the ﬁrst studies to evaluate the use
of carbohydrate counting in patients with
type 2 diabetes. Using a simple algorithm
to adjust mealtime insulin glulisine each
week based on SMBG patterns was as ef-
fective as adjusting mealtime insulin us-
ing insulin-to-carbohydrate ratios. Both
approaches yielded a reduction of about
1.5% in A1C with no signiﬁcant differ-
ences in mean A1C change from baseline
or in the percentage of patients achiev-
ing A1C goals of 6.5% (13) or 7.0%
(14). Both regimens were well tolerated.
The risk for severe hypoglycemia was low
and not signiﬁcantly different between
groups.
Other studies (15,16) have shown
that patients whose diabetes is well-
controlledwithinsulinoftenhaveabasal:
bolus insulin ratio close to 50%:50%. At
Table 2—Demographic and clinical characteristics and prior insulin treatment in the ITT
population
Characteristic Simple algorithm Carb count P value
n 136 137
Age (years) 55.1  8.8 (29–70) 55.0  9.5 (28–71) 0.8026
Sex
Male 53 (39.0) 67 (48.9) 0.2468
Female 83 (61.0) 70 (51.1)
Race
White 111 (81.6) 109 (79.6) 0.2776
Black 15 (11.0) 15 (10.9)
Asian/Oriental 2 (1.5) 0 (0.0)
Multiracial 0 (0.0) 1 (0.7)
Other 8 (5.9) 12 (8.8)
Height (cm) 169  10.6 (146–198) 170  9.8 (150–193) 0.4560
Weight (kg) 107  24.2 (61–187) 103  21.7 (52–171) 0.1217
BMI (kg/cm
2) 37.7  8.1 (21–63) 35.6  7.2 (17–60) 0.0416
A1C (%) 8.1  0.9 (7–10) 8.3  0.9 (6–11) 0.0825
FPG (mg/dl) 162  58.2 (49–306) 163  54.2 (52–341) 0.8112
Age at onset (year) 42.8  10.6 (13–66) 42.4  9.6 (14–63) 0.8594
Diabetes duration (years) 12.9  7.7 (0–40) 13.0  7.8 (0–36) 0.9055
Has subject used a pen for
insulin administration?
No 66 (48.5) 62 (45.3) 0.7788
Yes 69 (50.7) 75 (54.7)
Number of injections at
randomization
2 per day 43 (31.6) 57 (41.6) 0.0211
2 per day 93 (68.4) 80 (58.4)
Metformin used at
randomization
No 90 (66.2) 89 (65.0) 0.5793
Yes 46 (33.8) 48 (35.0)
Data are means  SD (range) or n (%).
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of insulin based on SMBG patterns, both
the simple algorithm and the carb count
groups had basal-bolus insulin ratios of
49%:51%. In addition, at the end of the
study, the bolus insulin dose was split be-
tween breakfast, lunch, and dinner: 27,
35, and 38% in the simple algorithm
group and 25, 34, and 41% in the carb
count group, respectively. At week 24,
both groups required large total daily in-
sulindoses(simplealgorithm1.9units/kg
and carb count 1.7 units/kg). The lower
total insulin doses for the carb count
grouppatientsmayreﬂectmorematching
of insulin doses to carbohydrate intake at
each meal as opposed to the set meal
doses of those in the simple algorithm
group.
In a recent study comparing three ap-
proachestostartingasingletypeofanalog
insulin in patients with type 2 diabetes
(basal, biphasic premixed, and prandial),
Holman et al. (17) concluded that al-
though each regimen improved glucose
control, most patients were likely to need
more than one type of insulin to achieve
target glucose levels. The percentages of
patients who achieved the target A1C of
the study (6.5%) were 8.1% basal,
17.0% biphasic, and 23.9% prandial. Al-
though one cannot directly compare in-
sulin regimens from different study
populations, it seems that diabetes in our
study population would be more difﬁcult
to control because patients had a longer
durationofdiabetesandweremoreobese
than subjects in the trial of Holman et al.
In the study reported here, however, pa-
tients with type 2 diabetes using basal:
bolus therapy achieved an A1C 6.5%
almost half of the time (simple algorithm
44.3% and carb count 49.5%).
Although basal-bolus insulin therapy
can improve glycemic control in type 1
(6,18) and type 2 (19,20) diabetes, the
most effective use of SMBG for adjusting
thebasal-bolusinsulindoseshasnotbeen
clearly established (21–24). Some feel
that postprandial monitoring is critical to
establishing good glycemic control,
whereas others are not convinced that
postprandial testing is essential (25). In
the present study, we showed that pa-
tients with type 2 diabetes using fasting
and mealtime SMBG testing alone to
monitor and adjust their rapid-acting and
long-acting insulin analogs achieved ex-
cellent glucose control as measured by
A1C, with minimal severe hypoglycemia.
The key elements of successful insu-
lin therapy are optimizing glycemic con-
trol while minimizing hypoglycemia.
Patients can learn to adjust mealtime in-
sulinbyeitherusingasimplealgorithmor
learning to use insulin-to-carbohydrate
ratios. Insulin-to-carbohydrate ratios al-
low ﬂexibility in food choices and enable
relatively precise matching of mealtime
insulin needs but can seem complex and
may be difﬁcult for some patients to im-
plement (10,11). We have shown that a
standard mealtime insulin glulisine dose
adjusted weekly on the basis of prepran-
dial blood glucose patterns can achieve
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Figure 2— A: A1C: change from baseline in simple algorithm and carb count groups at weeks 2, 6, 12, 18, and 24 (ITT population). B: FPG:
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mealtime insulin based on insulin-to-
carbohydrate ratios. It may be that our
simple algorithm group patients either
consumed fairly consistent amounts of
carbohydrates, thus minimizing needed
changes in insulin dosing, or learned to
modify their carbohydrate intake based
on SMBG measurements.
In summary, having two effective ap-
proaches to deliver and adjust rapid-
acting mealtime insulin (a simple
algorithm and insulin-to-carbohydrate
ratio) may increase patients’ and clini-
cians’ willingness to undertake basal:
bolus insulin therapy, a step that is often
neededtoachieveoptimalglucosecontrol
in type 2 diabetes.
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